PT  - JOURNAL ARTICLE
AU  - Marquardt, Viktoria
AU  - Theruvath, Johanna
AU  - Pauck, David
AU  - Picard, Daniel
AU  - Qin, Nan
AU  - Blümel, Lena
AU  - Maue, Mara
AU  - Bartl, Jasmin
AU  - Ahmadov, Ulvi
AU  - Langini, Maike
AU  - Meyer, Frauke-Dorothee
AU  - Cole, Allison
AU  - Cruz-Cruz, Joselyn
AU  - Graef, Claus M
AU  - Wölfl, Matthias
AU  - Milde, Till
AU  - Witt, Olaf
AU  - Erdreich-Epstein, Anat
AU  - Leprivier, Gabriel
AU  - Kahlert, Ulf
AU  - Stefanski, Anja
AU  - Stühler, Kai
AU  - Keir, Stephen T
AU  - Bigner, Darell D
AU  - Hauer, Julia
AU  - Beez, Thomas
AU  - Knobbe-Thomsen, Christiane B
AU  - Fischer, Ute
AU  - Felsberg, Jörg
AU  - Hansen, Finn K
AU  - Vibhakar, Rajeev
AU  - Venkatraman, Sujatha
AU  - Cheshier, Samuel H
AU  - Reifenberger, Guido
AU  - Borkhardt, Arndt
AU  - Kurz, Thomas
AU  - Remke, Marc
AU  - Mitra, Siddhartha
TI  - Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation
AID  - 10.1136/jitc-2022-005871
DP  - 2023 Jan 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - e005871
VI  - 11
IP  - 1
4099  - http://jitc.bmj.com/content/11/1/e005871.short
4100  - http://jitc.bmj.com/content/11/1/e005871.full
SO  - J Immunother Cancer2023 Jan 01; 11
AB  - Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.